Pretransplant mogamulizumab against ATLL might increase the risk of acute GVHD and non-relapse mortality

Bone Marrow Transplantation

Volumn 51, Issue 5, 2016, Pages 725-727

  Inoue, Y ^a,b   Fuji, S ^a,b   Tanosaki, R ^a   Fukuda, T ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b JUNTENDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MOGAMULIZUMAB; MONOCLONAL ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG SAFETY; FEMALE; HUMAN; INCIDENCE; LETTER; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SAFETY; PRIORITY JOURNAL; RISK ASSESSMENT; SURVIVAL RATE; SURVIVAL TIME; T CELL LEUKEMIA; TRANSPLANTATION CONDITIONING; ALLOTRANSPLANTATION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; MORTALITY; PREOPERATIVE PERIOD; PROGNOSIS; RETROSPECTIVE STUDY; TIME FACTOR; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA-LYMPHOMA, ADULT T-CELL; MALE; MIDDLE AGED; PREOPERATIVE PERIOD; PROGNOSIS; RETROSPECTIVE STUDIES; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84951310814     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2015.315     Document Type: Letter

References (10)

1. Matsuoka M, Jeang KT. Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer 2007; 7: 270-280.
2. Tsukasaki K, Utsunomiya A, Fukuda H, Shibata T, Fukushima T, Takatsuka Y et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemialymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol 2007; 25: 5458-5464.
3. Fukushima T, Nomura S, Shimoyama M, Shibata T, Imaizumi Y, Moriuchi Y et al. Japan Clinical Oncology Group (JCOG) prognostic index and characterization of long-term survivors of aggressive adult T-cell leukaemia-lymphoma (JCOG0902A). Br J Haematol 2014; 166: 739-748.
4. Yamamoto K, Utsunomiya A, Tobinai K, Tsukasaki K, Uike N, Uozumi K et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol 2010; 28: 1591-1598.
5. Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemialymphoma: a multicenter phase II study. J Clin Oncol 2012; 30: 837-842.
6. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing 11-2 receptor a-chains (CD25). J Immunol 1995; 155: 1151-1164.
7. Michael M, Shimoni A, Nagler A. Regulatory T cells in allogeneic stem cell transplantation. Clin Dev Immunol 2013; 2013: 608951.
8. Cohen JL, Trenado A, Vasey D, Klatzmann D, Salomon BL. CD4(+)CD25(+) immunoregulatory T cells: new therapeutics for graft-versus-host disease. J Exp Med 2002; 196: 401-406.
9. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4(+) CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 2002; 196: 389-399.
10. Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4 (+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 2002; 99: 3493-3499.